The lung microenvironment: an important regulator of tumour growth and metastasis

Research output: Contribution to journalReview article

Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, Jeffrey L. Port, Ashish Saxena, Brendon Stiles, Timothy McGraw, Vivek Mittal

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophysiological roles of the tumour microenvironment in lung cancer. In this Review, we highlight recent advances and emerging concepts for how the tumour-reprogrammed lung microenvironment promotes both primary lung tumours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis, immune modulation and response to therapies. We also discuss the potential of understanding tumour microenvironmental processes to identify biomarkers of clinical utility and to develop novel targeted therapies against lung cancer.

Original languageEnglish (US)
Pages (from-to)9-31
Number of pages23
JournalNature Reviews Cancer
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2019

PMID: 30532012

Altmetrics

Cite this

Standard

The lung microenvironment : an important regulator of tumour growth and metastasis. / Altorki, Nasser K.; Markowitz, Geoffrey J.; Gao, Dingcheng; Port, Jeffrey L.; Saxena, Ashish; Stiles, Brendon; McGraw, Timothy; Mittal, Vivek.

In: Nature Reviews Cancer, Vol. 19, No. 1, 01.01.2019, p. 9-31.

Research output: Contribution to journalReview article

Harvard

Altorki, NK, Markowitz, GJ, Gao, D, Port, JL, Saxena, A, Stiles, B, McGraw, T & Mittal, V 2019, 'The lung microenvironment: an important regulator of tumour growth and metastasis' Nature Reviews Cancer, vol. 19, no. 1, pp. 9-31. https://doi.org/10.1038/s41568-018-0081-9

APA

Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., ... Mittal, V. (2019). The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 19(1), 9-31. https://doi.org/10.1038/s41568-018-0081-9

Vancouver

Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer. 2019 Jan 1;19(1):9-31. https://doi.org/10.1038/s41568-018-0081-9

Author

Altorki, Nasser K. ; Markowitz, Geoffrey J. ; Gao, Dingcheng ; Port, Jeffrey L. ; Saxena, Ashish ; Stiles, Brendon ; McGraw, Timothy ; Mittal, Vivek. / The lung microenvironment : an important regulator of tumour growth and metastasis. In: Nature Reviews Cancer. 2019 ; Vol. 19, No. 1. pp. 9-31.

BibTeX

@article{2acc071680b148949576b42fbff30ee0,
title = "The lung microenvironment: an important regulator of tumour growth and metastasis",
abstract = "Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophysiological roles of the tumour microenvironment in lung cancer. In this Review, we highlight recent advances and emerging concepts for how the tumour-reprogrammed lung microenvironment promotes both primary lung tumours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis, immune modulation and response to therapies. We also discuss the potential of understanding tumour microenvironmental processes to identify biomarkers of clinical utility and to develop novel targeted therapies against lung cancer.",
author = "Altorki, {Nasser K.} and Markowitz, {Geoffrey J.} and Dingcheng Gao and Port, {Jeffrey L.} and Ashish Saxena and Brendon Stiles and Timothy McGraw and Vivek Mittal",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41568-018-0081-9",
language = "English (US)",
volume = "19",
pages = "9--31",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - The lung microenvironment

T2 - Nature Reviews Cancer

AU - Altorki, Nasser K.

AU - Markowitz, Geoffrey J.

AU - Gao, Dingcheng

AU - Port, Jeffrey L.

AU - Saxena, Ashish

AU - Stiles, Brendon

AU - McGraw, Timothy

AU - Mittal, Vivek

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophysiological roles of the tumour microenvironment in lung cancer. In this Review, we highlight recent advances and emerging concepts for how the tumour-reprogrammed lung microenvironment promotes both primary lung tumours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis, immune modulation and response to therapies. We also discuss the potential of understanding tumour microenvironmental processes to identify biomarkers of clinical utility and to develop novel targeted therapies against lung cancer.

AB - Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophysiological roles of the tumour microenvironment in lung cancer. In this Review, we highlight recent advances and emerging concepts for how the tumour-reprogrammed lung microenvironment promotes both primary lung tumours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis, immune modulation and response to therapies. We also discuss the potential of understanding tumour microenvironmental processes to identify biomarkers of clinical utility and to develop novel targeted therapies against lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=85058176429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058176429&partnerID=8YFLogxK

U2 - 10.1038/s41568-018-0081-9

DO - 10.1038/s41568-018-0081-9

M3 - Review article

VL - 19

SP - 9

EP - 31

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 1

ER -

ID: 43761164